Subscribe to RSS
DOI: 10.1055/s-0030-1262461
© Georg Thieme Verlag KG Stuttgart · New York
Der Weg in die personalisierte Therapie von gastrointestinalen Tumorerkrankungen – Möglichkeiten und Limitationen
Personalized therapy of gastrointestinal cancers – possibilities and limitationsPublication History
eingereicht: 21.4.2010
akzeptiert: 22.7.2010
Publication Date:
18 August 2010 (online)

Zusammenfassung
Es ist das Ziel einer palliativen Chemotherapie die Überlebensrate zu verbessern und gleichzeitig ein Maximum an Lebensqualität für die Betroffenen zu erhalten. Während wir einerseits noch immer die optimale Nutzung traditioneller Chemotherapeutika untersuchen, hat andererseits die Einführung zielgerichteter Therapien die therapeutischen Möglichkeiten bedeutend erweitert. Interessanterweise konnten aktuelle klinische Studien die zugrunde gelegten molekularen Konzepte nicht immer bestätigen. Neuere Daten weisen darauf hin, dass nicht Veränderungen in einzelnen Genen oder Signalwegen, sondern Veränderungen in Signaltransduktionsnetzwerken für die Entstehung und Propagation der meisten Tumore verantwortlich sind. Dies bedeutet, dass ein effektives therapeutisches Konzept pathophysiologisch relevante Signalnetze treffen muss und sich nicht darauf beschränken kann, nur einzelne Proteine zu inhibieren. Zweck dieser Übersichtsarbeit ist es aktuelle Konzepte und Probleme der Tumortherapie an beispielhaften Ergebnissen von klinischen Studien (limitiert auf Pankreaskarzinom und Kolonkarzinom) darzustellen und die derzeitige Interpretation dieser Ergebnisse zu diskutieren.
Abstract
The aim of palliative chemotherapy is to increase survival whilst maintaining optimal quality of life for the individual patient. While the best use of traditional chemotherapeutical agents continues to be explored, the introduction of targeted therapies has significantly broadened the therapeutic options. Yet it is interesting to note that the results of current trials did not always confirm the underlying molecular concepts. Recent data have suggested that altered pathways underlie the development of cancer, not just altered genes. Thus an effective therapeutic agent will have to target pathophysiologically relevant signalling networks, rather than individual proteins. This review presents current concepts and problems of cancer treatment, highlighting results from recent clinical trials of colorectal and pancreatic cancer patients and to discuss the current understanding of the underlying mechanisms.
Schlüsselwörter
Kolonkarzinom - Pankreaskarzinom - Signaltransduktion - targeted therapy
Keywords
colorectal cancer - pancreatic cancer - signal transduction - targeted personalized treatment
Literatur
- 1
Abou-Alfa G K, Schwartz L. et al .
Phase II study of sorafenib in patients with advanced hepatocellular
carcinoma.
J Clin Oncol.
2006;
24
4293-4300
MissingFormLabel
- 2
Amado R G, Wolf M. et al .
Wild-type
KRAS is required for panitumumab efficacy in patients with metastatic
colorectal cancer.
J Clin Oncol.
2008;
26
1626-1634
MissingFormLabel
- 3
Barault L, Veyrie N. et al .
Mutations
in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling
network correlate with poor survival in a population-based series
of colon cancers.
Int J Cancer.
2008;
122
2255-1159
MissingFormLabel
- 4
Baselga J, Arteaga C L.
Critical update
and emerging trends in epidermal growth factor receptor targeting
in cancer.
J Clin Oncol.
2005;
23
2445-2459
MissingFormLabel
- 5
Bos J L.
ras oncogenes in human cancer: a review.
Cancer Res.
1989;
49
4682-4689
MissingFormLabel
- 6
Brahimi-Horn M C, Chiche J, Pouyssegur J.
Hypoxia signalling controls metabolic demand.
Curr
Opin Cell Biol.
2007;
19
223-229
MissingFormLabel
- 7
Burris 3rd H A, Moore M J. et al .
Improvements in survival and clinical benefit
with gemcitabine as first-line therapy for patients with advanced
pancreas cancer: a randomized trial.
J Clin Oncol.
1997;
15
2403-2413
MissingFormLabel
- 8
Cascinu S, Berardi R. et al .
A combination
of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal
cancer patients. A GISCAD multicentre phase II study including a
biological analysis of EGFR overexpression, amplification and NF-kB
activation.
Br J Cancer.
2008;
98
71-76
MissingFormLabel
- 9
Cassidy J, Clarke S. et al .
Randomized
phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic
acid plus oxaliplatin as first-line therapy for metastatic colorectal
cancer.
J Clin Oncol.
2008;
26
2006-2012
MissingFormLabel
- 10
Chu E.
Molecular biomarker development for anti-EGFR therapy: moving beyond
EGFR expression.
Clin Colorectal Cancer.
2008;
7
162
MissingFormLabel
- 11
Demetri G D, van Oosterom A T. et al .
Efficacy and safety of sunitinib in patients with advanced gastrointestinal
stromal tumour after failure of imatinib: a randomised controlled
trial.
Lancet.
2006;
368
1329-1338
MissingFormLabel
- 12
Di Fiore F, Blanchard F. et al .
Clinical
relevance of KRAS mutation detection in metastatic colorectal cancer
treated by Cetuximab plus chemotherapy.
Br J Cancer.
2007;
96
1166-9116
MissingFormLabel
- 13
Escudier B, Eisen T. et al .
Sorafenib
in advanced clear-cell renal-cell carcinoma.
N Engl J
Med.
2007;
356
125-134
MissingFormLabel
- 14
Folkman J.
Tumor angiogenesis: therapeutic implications.
N Engl
J Med.
1971;
285
1182-1186
MissingFormLabel
- 15
Folkman J, Merler E. et al .
Isolation
of a tumor factor responsible for angiogenesis.
J Exp
Med.
1971;
133
275-288
MissingFormLabel
- 16
Folprecht G, Seymour M T. et al .
Irinotecan/fluorouracil
combination in first-line therapy of older and younger patients
with metastatic colorectal cancer: combined analysis of 2,691 patients
in randomized controlled trials.
J Clin Oncol.
2008;
26
1443-1451
MissingFormLabel
- 17
Frattini M, Saletti P. et al .
PTEN
loss of expression predicts cetuximab efficacy in metastatic colorectal
cancer patients.
Br J Cancer.
2007;
97
1139-1145
MissingFormLabel
- 18
Furukawa T.
Molecular targeting therapy for pancreatic cancer: current knowledge
and perspectives from bench to bedside.
J Gastroenterol.
2008;
43
905-911
MissingFormLabel
- 19
Gomez-Manzano C, Holash J. et al .
VEGF
Trap induces antiglioma effect at different stages of disease.
Neuro Oncol,.
2008;
10
940-945
MissingFormLabel
- 20
Grothey A.
A comparison of XELOX with FOLFOX-4 as first-line treatment for
metastatic colorectal cancer.
Nat Clin Pract Oncol.
2009;
6
10-11
MissingFormLabel
- 21
Hau P, Jachimczak P. et al .
Inhibition
of TGF-beta2 with AP 12 009 in recurrent malignant gliomas:
from preclinical to phase I/II studies.
Oligonucleotides.
2007;
17
201-212
MissingFormLabel
- 22
Hecht J R, Mitchell E. et al .
A randomized
phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared
with chemotherapy and bevacizumab alone for metastatic colorectal
cancer.
J Clin Oncol.
2009;
27
672-680
MissingFormLabel
- 23
Heidorn S J, Milagre C. et al .
Kinase-dead
BRAF and oncogenic RAS cooperate to drive tumor progression through
CRAF.
Cell.
2010;
140
209-221
MissingFormLabel
- 24
Hurwitz H.
Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab
with chemotherapy in advanced colorectal cancer.
Clin
Colorectal Cancer.
2004;
4 Suppl 2
S62-68
MissingFormLabel
- 25
Hurwitz H, Fehrenbacher L. et al .
Bevacizumab
plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal
cancer.
N Engl J Med.
2004;
350
2335-2342
MissingFormLabel
- 26
Italiano A, Follana P. et al .
Cetuximab
shows activity in colorectal cancer patients with tumors for which
FISH analysis does not detect an increase in EGFR gene copy number.
Ann Surg Oncol.
2008;
15
649-654
MissingFormLabel
- 27
Jhawer M, Goel S. et al .
PIK3CA mutation/PTEN
expression status predicts response of colon cancer cells to the
epidermal growth factor receptor inhibitor cetuximab.
Cancer
Res.
2008;
68
1953-1961
MissingFormLabel
- 28
Jones S, Zhang X. et al .
Core signaling
pathways in human pancreatic cancers revealed by global genomic
analyses.
Science.
2008;
321
1801-1806
MissingFormLabel
- 29
Kabbinavar F F, Hambleton J. et al .
Combined
analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin
improves survival for patients with metastatic colorectal cancer.
J Clin Oncol.
2005;
23
3706-3712
MissingFormLabel
- 30
Karapetis C S, Khambata-Ford S. et al .
K-ras
mutations and benefit from cetuximab in advanced colorectal cancer.
N Engl J Med.
2008;
359
1757-1765
MissingFormLabel
- 31
Khambata-Ford S, Garrett C R. et al .
Expression
of epiregulin and amphiregulin and K-ras mutation status predict
disease control in metastatic colorectal cancer patients treated
with cetuximab.
J Clin Oncol.
2007;
25
3230-3237
MissingFormLabel
- 32
Kim K J, Li B. et al .
Inhibition
of vascular endothelial growth factor-induced angiogenesis suppresses
tumour growth in vivo.
Nature.
1993;
362
841-844
MissingFormLabel
- 33
Kindler H L, Friberg G. et al .
Phase
II trial of bevacizumab plus gemcitabine in patients with advanced
pancreatic cancer.
J Clin Oncol.
2005;
23
8033-8040
MissingFormLabel
- 34
Lievre A, Bachet J B. et al .
KRAS
mutations as an independent prognostic factor in patients with advanced
colorectal cancer treated with cetuximab.
J Clin Oncol.
2008;
26
374-379
MissingFormLabel
- 35
Malumbres M, Barbacid M.
RAS oncogenes: the
first 30 years.
Nat Rev Cancer.
2003;
3
459-465
MissingFormLabel
- 36
Mendelsohn J, Baselga J.
Status of epidermal
growth factor receptor antagonists in the biology and treatment
of cancer.
J Clin Oncol.
2003;
21
2787-2799
MissingFormLabel
- 37
Messersmith W A, Ahnen D J.
Targeting EGFR
in colorectal cancer.
N Engl J Med.
2008;
359
1834-1836
MissingFormLabel
- 38
Meyerhardt J A, Mayer R J.
Systemic therapy
for colorectal cancer.
N Engl J Med.
2005;
352
476-487
MissingFormLabel
- 39
Miller K, Wang M. et al .
Paclitaxel
plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
N Engl J Med.
2007;
357
2666-2676
MissingFormLabel
- 40
Moore M J, Goldstein D. et al .
Erlotinib
plus gemcitabine compared with gemcitabine alone in patients with
advanced pancreatic cancer: a phase III trial of the National Cancer
Institute of Canada Clinical Trials Group.
J Clin Oncol,.
2007;
25
1960-1966
MissingFormLabel
- 41
Moroni M, Sartore-Bianchi A. et al .
EGFR
FISH in colorectal cancer: what is the current reality?.
Lancet
Oncol.
2008;
9
402-403
MissingFormLabel
- 42
Motzer R J, Michaelson M D. et al .
Activity of SU11248, a multitargeted inhibitor of vascular endothelial
growth factor receptor and platelet-derived growth factor receptor,
in patients with metastatic renal cell carcinoma.
J Clin
Oncol.
2006;
24
16-24
MissingFormLabel
- 43
Olive K P, Jacobetz M A. et al .
Inhibition
of Hedgehog signaling enhances delivery of chemotherapy in a mouse
model of pancreatic cancer.
Science.
2009;
324
1457-1461
MissingFormLabel
- 44
Parsons D W, Jones S. et al .
An integrated
genomic analysis of human glioblastoma multiforme.
Science.
2008;
321
1807-1812
MissingFormLabel
- 45
Philip P A.
Targeted therapies for pancreatic cancer.
Gastrointest
Cancer Res.
2008;
2
S16-19
MissingFormLabel
- 46
Poulikakos P I, Zhang C. et al .
RAF inhibitors
transactivate RAF dimers and ERK signalling in cells with wild-type
BRAF.
Nature.
2010;
464
427-430
MissingFormLabel
- 47
Punt C J, Koopman M.
Capecitabine and irinotecan
as first-line treatment of advanced colorectal cancer.
J
Clin Oncol.
2008;
26
1907-1908; author reply 1908 – 1909
MissingFormLabel
- 48
Saltz L B, Lenz H J. et al .
Randomized
phase II trial of cetuximab, bevacizumab, and irinotecan compared
with cetuximab and bevacizumab alone in irinotecan-refractory colorectal
cancer: the BOND-2 study.
J Clin Oncol.
2007;
25
4557-4561
MissingFormLabel
- 49
Schiller J H.
Developments in epidermal growth factor receptor-targeting therapy
for solid tumors: focus on matuzumab (EMD 72 000).
Cancer
Invest.
2008;
26
81-95
MissingFormLabel
- 50
Scholl C, Frohling S. et al .
Synthetic
lethal interaction between oncogenic KRAS dependency and STK33 suppression
in human cancer cells.
Cell.
2009;
137
821-834
MissingFormLabel
- 51
Thomas A L, Morgan B. et al .
Phase
I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics
of PTK787/ZK 222 584 administered twice daily
in patients with advanced cancer.
J Clin Oncol.
2005;
23
4162-4171
MissingFormLabel
- 52
Thomas A L, Trarbach T. et al .
A phase
IB, open-label dose-escalating study of the oral angiogenesis inhibitor
PTK787/ZK 222 584 (PTK/ZK), in combination
with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
Ann Oncol.
2007;
18
782-788
MissingFormLabel
- 53
Tol J, Koopman M. et al .
Chemotherapy,
bevacizumab, and cetuximab in metastatic colorectal cancer.
N
Engl J Med.
2009;
360
563-572
MissingFormLabel
- 54
Tyagi P.
Recent results and ongoing trials with panitumumab (ABX-EGF), a
fully human anti-epidermal growth factor receptor antibody, in metastatic
colorectal cancer.
Clin Colorectal Cancer.
2005;
5
21-23
MissingFormLabel
- 55
Tyagi P.
Vatalanib (PTK787/ZK 222 584) in combination
with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal
cancer: preliminary results from the CONFIRM-1 trial.
Clin
Colorectal Cancer.
2005;
5
24-26
MissingFormLabel
- 56
Van Cutsem E, van de Velde H. et al .
Phase
III trial of gemcitabine plus tipifarnib compared with gemcitabine
plus placebo in advanced pancreatic cancer.
J Clin Oncol.
2004;
22
1430-1438
MissingFormLabel
- 57
Van Cutsem E, Kohne C H. et al .
Cetuximab
and chemotherapy as initial treatment for metastatic colorectal
cancer.
N Engl J Med.
2009;
360
1408-1417
MissingFormLabel
- 58
Van Cutsem E, Vervenne W L. et al .
Phase
III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib
in Patients With Metastatic Pancreatic Cancer.
J Clin
Oncol.
2009;
13
2231-2237
MissingFormLabel
- 59
Vetter I R, Wittinghofer A.
The guanine nucleotide-binding
switch in three dimensions.
Science.
2001;
294
1299-304
MissingFormLabel
- 60
von Wichert G, Seufferlein T, Adler G.
Palliative treatment of pancreatic cancer.
J Dig Dis.
2008;
9
1-7
MissingFormLabel
- 61
Wood L D, Parsons D W. et al .
The
genomic landscapes of human breast and colorectal cancers.
Science.
2007;
318
1108-1113
MissingFormLabel
- 62
Yu J L, Rak J W. et al .
Effect
of p53 status on tumor response to antiangiogenic therapy.
Science.
2002;
295
1526-1528
MissingFormLabel
Prof. Thomas Seufferlein
Klinik für Innere Medizin I, Universität
Halle
Ernst Grube Straße 40
06120 Halle
Phone: 0345/5572661
Fax: 0345/5572053
Email: thomas.seufferlein@medizin.uni-halle.de